地中海欧洲地区基于整合酶的一线HIV抗逆转录病毒方案的传播性耐药
MeditRes联盟纳入2018-2021年法国、希腊、意大利、葡萄牙和西班牙新诊断未治疗HIV感染者2705例,评估整合酶链转移抑制剂和核苷/核苷酸逆转录酶抑制剂的传播性耐药及临床相关耐药。整合酶监测耐药突变率为0.30%,临床相关耐药对多替拉韦/比克替拉韦为0.15%,对第二代整合酶抑制剂和一线NRTI的临床相关耐药率低,新诊断者基线耐药可能性小。
要点
- 整合酶监测耐药突变率0.30%,NRTI监测耐药突变率5.77%。
- 整合酶临床相关耐药率2.33%,其中多替拉韦/比克替拉韦0.15%。
- 对一线NRTI临床相关耐药率1.74%。
核心结论
- 2018-2021年MeditRes国家新诊断PWH对基于第二代整合酶抑制剂的一线方案基线耐药可能性小。
研究设计与样本
- MeditRes联盟纳入2018-2021年法国、希腊、意大利、葡萄牙和西班牙新诊断未治疗PWH,共2705例,72%男性,中位年龄37岁(IQR 30-48),43.7%为非B亚型。
主要发现
- 整合酶监测耐药突变率为0.30%(T66I、T66A、E92Q、E138T、E138K、Y143R、S147G、R263K各n=1)。
- NRTI监测耐药突变率为5.77%(M184V 0.85%、M184I 0.18%、K65R/N 0.11%、K70E 0.07%、L74V/I 0.18%、任何胸苷类似物突变4.36%)。
- 整合酶临床相关耐药率为2.33%(多替拉韦/比克替拉韦0.15%,拉替拉韦/埃替拉韦2.29%)。
- 对一线NRTI临床相关耐药率为1.74%(替诺福韦/替诺福韦艾拉酚胺0.89%,阿巴卡韦1.74%,拉米夫定/恩曲他滨1.07%)。
关键数值与推荐
- 临床相关耐药定义为任何耐药水平≥3,采用Stanford HIV耐药数据库v.9.1算法。
- 监测耐药突变采用Stanford HIV网站校准群体耐药工具。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated the prevalence of transmitted drug resistance (TDR) to integrase strand-transfer inhibitors (INSTIs) and nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and of clinically relevant resistance (CRR) in newly diagnosed people with human immunodeficiency virus (HIV; PWH) naive to antiretroviral therapy (ART) in Europe. METHODS: MeditRes is a consortium that includes ART-naive PWH newly diagnosed in France, Greece, Italy, Portugal, and Spain during 2018-2021. Reverse transcriptase and INSTI sequences were provided by participating centers. To evaluate the prevalence of surveillance drug resistance mutations (SDRM), we used the calibrated population resistance tools from the Stanford HIV website. To evaluate CRR, defined as any resistance level ≥3, we used the Stanford HIV Drug Resistance Database v.9.1 algorithm. RESULTS: We included 2705 PWH, 72% men, median age of 37 years (interquartile range, 30-48); 43.7% were infected by non-B subtypes. The prevalence of INSTI-SDRMs was 0.30% (T66I, T66A, E92Q, E138T, E138K, Y143R, S147G, R263K; all n=1) and the prevalence of NRTI-SDRMs was 5.77% (M184V: 0.85%; M184I: 0.18%; K65R/N: 0.11%; K70E: 0.07%; L74V/I: 0.18%; any thymidine analog mutations: 4.36%). INSTI-CRR was 2.33% (0.15% dolutegravir/bictegravir, 2.29% raltegravir/elvitegravir) and 1.74% to first-line NRTIs (0.89% tenofovir/tenofovir alafenamide, 1.74% abacavir, 1.07% lamivudine/emtricitabine). CONCLUSIONS: We present the most recent data on TDR to integrase-based first-line regimens in Europe. Given the low prevalence of CRR to second-generation integrase inhibitors and to first-line NRTIs during 2018-2021, it is unlikely that newly diagnosed PWH in MeditRes countries would present with baseline resistance to a first-line regimen based on second-generation integrase inhibitors.
引用
- de Salazar A, Viñuela L, Fuentes A, et al. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe. Clin Infect Dis. 2023. PMID: 36571282. doi:10.1093/cid/ciac972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。